Public reporting of health care data continues to proliferate as consumers and other stakeholders seek information on the quality and outcomes of care. Medicare's Hospital Compare website, the U.S. News & World Report hospital rankings, and several state-level programs are well known. Many rely heavily on administrative data as a surrogate to reflect clinical reality. Clinical data are traditionally more difficult and costly to collect, but more accurately reflect patients' clinical status, thus enhancing the validity of quality metrics. We describe the public reporting effort being launched by the American College of Cardiology and partnering professional organizations using clinical data from the National Cardiovascular Data Registry (NCDR) programs. This hospital-level voluntary effort will initially report process of care measures from the percutaneous coronary intervention (CathPCI) and implantable cardioverter-defibrillator (ICD) registries of the NCDR. Over time, additional process, outcomes, and composite performance metrics will be reported. (J Am Coll Cardiol 2016;67:205-15)
Traditionally, NCDR data have only been available directly to participant facilities, consortia, or health plans. Several scientific publications from the NCDR have reported aggregate data to identify quality gaps at the national level to stimulate efforts to improve care (11) . Now, the ACC, in partnership with Society for Cardiovascular Angiography and Interventions and Heart Rhythm Society, has developed a pathway for participant institutions to voluntarily publicly report their NCDR hospital-level data (1, 12) .
RATIONALE FOR PUBLIC REPORTING
The most compelling justification for public reporting is the right of an individual to know about the care that he or she is likely to receive. With the current national emphasis on the quality, accountability, and cost-effectiveness of health care, the various stakeholders and consumers of health care are eager to obtain information about health care facilities and providers. This has created a "market" for public reporting that, at present, is not well coordinated as different stakeholders have somewhat divergent goals and varying confidence in the utility of nonclinical data sources ( Figure 1 ). Many public reports use data that are several years old, were not designed for clinical performance reporting, or are constructed using proprietary analytic methods that are difficult to reproduce or verify. This diverse reporting environment can confuse patients and purchasers, has the potential to misdirect our focus away from the rights of the individual patient, and has led to divergent public rankings of the same facility in different reporting systems (13) .
Hospital-level public reporting, in its various formats, is now familiar to most clinicians. Public reporting of individual provider data is becoming more prevalent (14). However, physician-level reporting has additional challenges, such as attributing process and outcome of care metrics to specific providers and addressing variability in individual metrics in smaller practice groups or for individuals.
Public reporting is primarily based upon the belief that accessible, transparent high-quality information will affect decisions and behaviors of the various stakeholders, ultimately resulting in an improvement in health care delivery and outcomes. However, use of this information by various segments of the population is variable, and the effect of this information on patients' decision-making is uncertain (15, 16) .
Reporting efforts to define the "best of the best" can motivate an unnecessary performance-reporting race and may not provide the information most patients are seeking. Patients' quality concerns seem more focused on access to empathetic, interactive providers and the availability of local common services that meet an acceptable standard of care (17) (18) (19) (20) . As public reporting efforts continue to grow, the ACC and its partnering organizations are committed to a leadership role in quality of care ACC believes it has a responsibility to move the profession toward acceptance of public reporting by using clinical data from the NCDR. Therefore, after careful study of the feasibility of public reporting using NCDR data, the ACC and its partnering organizations established the Public Reporting Advisory Group to oversee the implementation of the public reporting program and guide operational decisions necessary to achieve these goals. A summary of the key decisions made by the Public Reporting Advisory Group and the structure of the public reporting program are described in this paper.
STRUCTURE OF THE PUBLIC REPORTING PROGRAM AND THE INITIAL METRICS REPORTED
Major operational decisions about the structure of the reporting program are summarized in Table 1 .
Hospital participation in public reporting of their NCDR data is voluntary. Because metrics reported in Facility identification All facilities participating in at least 1 NCDR registry will have an opening page that identifies the site, address, contact information, and services performed at the facility based upon self-reported information. A link to Google maps is provided. Facilities may provide a link to their organization's website if desired.
Facility participation Facility participation in public reporting is voluntary. Facilities that choose not to participate in reporting will be designated as "not participating in ACC/NCDR public reporting program"
Registry participation Facility participation in each of the NCDR registries will be identified. The terms used are "participating" if the service is performed at the facility and data are submitted to the corresponding NCDR registry; "not participating" if the service is performed at the facility, but the facility does not submit data to the associated registry; and "does not perform service" if the service is not performed at the facility Registry reporting Facilities submitting data to more than 1 registry may choose to participate in public reporting for each registry individually. However, all individual metrics within a registry will be reported provided they meet the minimum sample size requirements. This initial launch will be limited to measures from the CathPCI and ICD registries.
Facility review period Facilities will receive data contained in their public report a minimum of 30 days before the release date. During that review period, facilities will decide to opt in for this cycle of public reporting.
Reporting frequency For public reporting, data are displayed using a 12-month, calendar year performance period. Public reports will be issued and updated once per calendar year based on the most recent calendar year data available.
Data requirements Data are evaluated for completeness and logic before entry into an NCDR registry. Data are entered quarterly, and only those data submissions passing these checks are accepted into the registry. For public reporting, facilities must have submitted acceptable data for a minimum of 9 months during the calendar year period. Facilities failing this requirement are ineligible for public reporting.
Rating format
The public display will use a 1-to 4-star rating scheme. Each metric from a facility will have a star rating assigned; there will be no zero star ratings, and only whole star ratings are presented. Additional details about the rating including confidence interval estimates are provided by links to web pages with detailed explanations.
Hospital comparison data
Each hospital will receive a performance score for each reported metric converted to the star rating. This score can be used to assess individual hospital performance compared with a benchmark of other facilities eligible to report data. A higher performance score means better performance on the metric.
State comparison data
Each state also receives a quality performance score converted to a star rating. This score can be used to assess the performance of all hospitals in the state compared with a benchmark of all states with registry data. A higher performance score means better performance on the metric for all hospitals across the state. The number of PCI/angioplasty procedures that a site performs does not necessarily indicate higher quality, but it may be an indication of how experienced this site is with the procedure.
Aspirin at discharge (8) 0964
Use of aspirin to reduce the chance of blood clots after PCI/angioplasty.
Patients should be prescribed aspirin to reduce the risk of heart attacks caused by blood clots in new stents after having a PCI/angioplasty-unless there is a reason not to use the medicine (such as an allergy). This score shows how well this facility is following this guideline-higher is better. Patients who cannot take aspirin are excluded from the calculation.
P2Y 12 inhibitor at discharge (9) 0964 Use of a P2Y 12 inhibitor medication to reduce the chance of blood clots after PCI/angioplasty.
Patients should be prescribed a P2Y 12 inhibitor medication to reduce the risk of heart attacks caused by blood clots in new stents after having a PCI/angioplasty-unless there is a reason not to use the medicine (such as an allergy). This score shows how well this facility is following this guideline-higher is better. Patients who cannot take P2Y 12 inhibitor medicines are excluded from the calculation.
Statins at discharge (10) 0964 Use of a statin to decrease cholesterol after PCI/angioplasty.
Patients should be prescribed a statin to decrease cholesterol and reduce the risk of heart attacks after having a PCI/angioplasty-unless there is a reason not to use the medicine (such as an allergy). This score shows how well this facility is following this guideline-higher is better. Patients who cannot take statin medications are excluded from the calculation.
Composite of all medications at discharge (aspirin, P2Y 12 inhibitor, and statin) (N/A) 0964 Use of all recommended medications (aspirin, P2Y 12 inhibitor medication, and statin) to reduce the chance of blood clots and decrease cholesterol after PCI/angioplasty.
Patients should be prescribed aspirin, a P2Y 12 inhibitor medication, and a statin medication after having a PCI/angioplasty to reduce the chance of blood clots in new stents, decrease cholesterol, and reduce the risk of heart attacks-unless there is a reason not to use these medicines (such as an allergy). This score shows how well this facility is following this guideline-higher is better. Patients who cannot take a recommended medicine are excluded.
Terms, such as P2Y12, that may be unfamiliar to the public are all defined in an online dictionary available to the public.
NQF ¼ National Quality Forum; PCI ¼ percutaneous coronary intervention; other abbreviations as in Table 1 .
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STATISTICAL ANALYSIS AND DISPLAY OF REPORTED VARIABLES
To address some of the uncertainty due to sample size, a model-based approach was adopted rather than using the actual observed fraction of eligible patients who receive a therapy as the reported value.
The model provides an estimate of the hospital's probability of providing a therapy among patients identified as eligible for the therapy. For example, if a recommended drug were given to 10 of 11 patients
receiving an ICD at a facility, the computed (observed) performance score would be 91%. Because of the small sample size, the computed score of 91% could be an incorrect assessment of the facility's true performance, and the resulting confidence intervals would be wide. The model-based approach described in the Online Appendix accounts for both the "noise" asso- The number of ICD implant procedures that a site performs does not necessarily indicate higher quality, but it may be an indication of how experienced this site is with the procedure.
HF/LVSD: ACEI/ARB therapy at discharge (4) 1522 Use of a medicine in the ACEi or ARB class to improve heart function after ICD implant in patients with less than normal heart function.
Patients with less than normal heart function should be prescribed an ACEI or ARB medication after receiving an ICD implant-unless there is a reason not to use the medicine (such as an allergy). Use of this medication may reduce the risk of death and hospital readmission after this procedure. This score shows how well this facility is following this guideline-higher is better. Patients who cannot take an ACEI or ARB are excluded from the calculation.
CAD/MI beta-blocker at discharge (5) 1528 Use of a beta-blocker medication after ICD implant in patients with a previous heart attack.
Patients who have experienced a previous heart attack should be prescribed a beta-blocker medication after receiving an ICD implant-unless there is a reason not to use the medicine (such as an allergy). Use of this medication may reduce the risk of death and hospital readmission after this procedure. This score shows how well this facility is following this guideline-higher is better. Patients who cannot take beta-blocker medicines are excluded from the calculation.
HF/LVSD: beta-blocker at discharge (6) 1529 Use of a beta-blocker medication after ICD implant in patients with less than normal heart function.
Patients with less than normal heart function should be prescribed a beta-blocker medication after receiving an ICD implant-unless there is a reason not to use the medicine (such as an allergy). Use of this medication may reduce the risk of death and hospital readmission after this procedure. This score shows how well this facility is following this guideline-higher is better. Patients who cannot take beta-blocker medicines are excluded from the calculation.
Composite of all medications at discharge (ACEI/ARB and beta-blocker) (14) 0965 Use of all recommended medications (ACEI or ARB and beta-blocker) to improve heart function and blood pressure after ICD implant.
Patients should be prescribed an ACEI or ARB medication and a beta-blocker medication after receiving an ICD implant-unless there is a reason not to use these medicines (such as an allergy). Use of these medications may reduce the risk of death and hospital readmission after this procedure. This score shows how well this facility is following this guideline-higher is better.
Patients who cannot take a recommended medicine are excluded.
Medical terms that may be unfamiliar to the public are all defined in an online dictionary available to the public.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; CAD ¼ coronary artery disease; HF ¼ heart failure; LVSD ¼ left ventricular systolic dysfunction; MI ¼ myocardial infarction; other abbreviations as in Tables 1 and 2. sample size and a score below the mean of all hospitals is "pulled up" closer to the mean score of all hospitals.
The amount a score is adjusted up or down by the model depends on the number of cases it contributes.
This method better predicts future performance than the point estimate provided by observed rates.
Although more challenging to explain to hospitals and the public, this approach is commonly used in other reporting efforts such as Hospital Compare and adheres to standards for public reporting of outcome measures (9, 47) . This is consistent with the ACC's position that the motivation behind public reporting should be the promotion of best practices and quality improvement rather than creating unjustified apparent differentiation across facilities (7).
The information provided in public reporting should be understandable and usable. The amount of information and manner in which it is displayed determine whether consumers can actually process and use it in decision-making (48, 49) . Information displays that aid consumers in quickly understanding the meaning of data increase consumer motivation to use the information, in contrast to a bewildering display that will quickly be dismissed as too complicated. On the basis of recommendations from several sources and the previously cited best practices for public reporting documents, we adopted a 1 to 4 starrating scheme.
Once a facility's performance score for a measure is estimated from the model, the score is converted to a star rating for public display. To avoid confusion, the same scheme for the star assignments of performance scores is used throughout the reporting program rather than using a different scheme for star rating assignment for individual metrics. Among the options considered to convert the modeled score to stars, an absolute scoring option was chosen. The primary benefit of absolute performance scoring is that performance scores are converted into star ratings based on cut-points that were deemed clinically relevant and that would yield meaningful clinical differences between groups. However, a potential drawback is the possibility to have no (or all) hospitals assigned to a specific star tier, and thus, this display could provide little discrimination between hospitals for the consumer. In addition, there is subjectivity to the thresholds, as not all may agree on clinically meaningful threshold values.
The cut points chosen for star assignments were:
1 star for a performance score <75%, 2 stars for performance scores $75% but <90%, 3 stars for performance scores $90% but <95% and 4 stars for a performance score $95%.
DISPLAY OF UNCERTAINTY
The hierarchical model-based approach used in reporting will adjust for some of the uncertainty in the performance scores related to sample size. 
THE FUTURE OF NCDR PUBLIC REPORTING
This first iteration of public reporting by the ACC follows the principles set forth in the NCDR public reporting program mission statement ( Table 4 ).
The NCDR acknowledges that this is only the initial step in our public reporting program. There are Monitor the quality of cardiovascular patient care being provided in a transparent manner.
Ensure reporting is based on data that is of high quality, is administered with minimal collection burden as cost-effectively as reasonable, and employs clinically valid and methodologically sound measures.
Provide measures that are actionable and consistent with the triple aim of better outcomes, better care, and lower costs without causing unintended consequences in access to care for any population.
Focus on measures that include aspects of care where the patient can be engaged as part of the solution or where there is clear evidence that individual patient engagement can have an effect on the care being provided.
Foster relationships of trust through collaboration between patients and their cardiovascular care team by presenting information that is credible, understandable, and actionable. several important reasons for hospitals to participate in the NCDR public reporting programs. First, the public has a growing desire for this information; thus, providing these NCDR data demonstrates a good faith effort to deliver high-quality clinical data to assist patients' health care decisions. Second, value-driven purchasing, which will include public access to provider performance, will be dominant within several years. Failure to understand and use clinical data now to improve operations may result in facilities falling subject to public judgments based on administrative or proprietary-derived data and falling behind in their adaptation to the changing health care environment (57) . Finally, all major cardiovascular professional organizations support patient advocacy, serve members' practice advancement, and promote quality education programs for their members, and many support clinical databases (8, 10) . These registries use standardized, timely, benchmarked reports to document best practices and outcomes and aid participants to improve operations and services.
These data are also used for member recertification and the documentation of competencies. This approach harmonizes into the value-purchasing paradigm that is rapidly approaching.
The ACC recognizes that reporting alone is not sufficient to drive improvements in care delivery and will continue to build Clinical Toolkits as part of the Quality Improvement for Institutions initiative made available at no cost to every NCDR participating facility (10) . NCDR data are used to identify gaps in care as priority topics for toolkit development, and the toolkit resources are focused to align specifically with the patient care goals being measured through NCDR.
Future public reporting using NCDR data may include use of validated quality metrics, riskadjusted clinical outcomes, and composite quality measures across NCDR registries. For some of these outcome measures, it will be necessary to link 
